Delivering tomorrow’s
genetic medicines,

With the emergence of gene therapies, we are at a crucial turning point in human history.
In our lifetimes, we will see major diseases become treatable or curable thanks to this new therapeutic approach.
At NanoVation TherapeuticsTM (NTx), we are making this future a reality by enabling the safe and efficient delivery of genetic medicines to target tissues in the body.
OUR PURPOSE:
OUR MISSION:

Our next-generation platform technologies use lipid nanoparticles to deliver nucleic acids to a variety of tissues
NTx develops scalable, nucleic acid-agnostic lipid nanoparticle (LNP) formulations customized for specific targets, payloads and routes of administration.
NanoVation Therapeutics™ provides a leading one-stop-shop IP portfolio to empower your genetic medicines
Our multidisciplinary team includes world-leading experts in lipid chemistry, RNA design and nucleic acid delivery
NanoVation Therapeutics™ is headquartered in Vancouver, BC, Canada
Founded in Vancouver, NanoVation Therapeutics™ is establishing an international chain of innovation hubs (NanoVation GENErators™) in strategic locations worldwide.

International headquarters
4th Floor, 2405 Wesbrook Mall, Vancouver BC V6T 1Z3, Canada
NanoVation Therapeutics™
4th Floor, 2405 Wesbrook Mall
Vancouver BC V6T 1Z3
Canada
UK NanoVation GENErator™
Harwell Science and Innovation Campus, Oxford, UK OX11 0FA
UK NanoVation GENErator™
Hartwell Science & Innovation Campus
Oxford, Didcot OX11 0RL
United Kingdom

NT toolbox
LNP compositions
NTx develops scalable, nucleic acid-agnostic lipid nanoparticle (LNP) formulations customized for specific tissues, different nucleic acid payloads and routes of administration.
- Novel in-house lipids to formulate lipid nanoparticles (LNPs) encapsulating a variety of payloads (siRNA, mRNA, pDNA, etc.).
- Formulated LNPs analyzed for nucleic acid and lipid content, entrapment, particle size and polydispersity.
- LNP compositions for hepatropic and local delivery.
The long-circulating LNP (lcLNP™)
NanoVation’s flagship technology – the long-circulating LNP (lcLNP™) – enables the functional delivery of nucleic acids to extrahepatic tissues including bone marrow, tumors, and skin.
- Extended systemic circulation for efficient extrahepatic delivery.

NT toolbox
Surface modifications
NTx expands the range of surface modifications to improve tolerability and increase target specificity.

NT toolbox
mRNA modifications
NTx develops new mRNA modifications and manufacturing strategies that improve expression kinetics and storage stability while increasing translation and cellular specificity.
- In-house in vitro mRNA synthesis from DNA templates with optimized translational efficiency and stability
- Different mRNA constructs available for a variety of biological applications.
- In vitro transcribed mRNA characterized for purity, capping efficiency and endotoxin levels
- Novel proprietary RNA caps that greatly increase the efficiency of mRNA translation